Delta-Fly Pharma Adjusts Exercise Price

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 2, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Delta-Fly Pharma Adjusts Exercise Price and Minimum Exercise Price for Ninth Tranche Warrant

Source disclosure: February 02, 2026 Delta-Fly Pharma,Inc. [4598.T] TOKYO, Feb 02 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) announced adjustments to the exercise price and minimum exercise price for its ninth tranche warrant due to the issuance of the eleventh tranche warrant to Macquarie Bank Limited, as decided by the board meeting held on January 16, 2026. According to the notice, the exercise price and minimum exercise price for Delta-Fly Pharma shares will be adjusted